POLYMED.NS Stock Analysis
PO
Avoid
Based on Eyestock quantitative analysis, POLYMED.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Poly Medicure Ltd. engages in the provision and sales of medical devices. The company is headquartered in Faridabad, Haryana and currently employs 2,339 full-time employees. The company went IPO on 2011-12-05. The firm is primarily in the business of manufacture and sale of medical devices. The firm offers a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, covid care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. The company supplies its products to approximately 120 countries, in Europe, Africa, Americas, Australia, and Asia. Its products include suction control valve, safety arterial cannula, VTM Kit, VLTM kit, blood collection needle with flashback, and pre-filled syringes. The firm operate nine manufacturing facilities across India, China, Egypt, and Italy. In India, it operates six manufacturing facilities, four of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand).